We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




New Sandwich Biosensor Developed for Tuberculosis Diagnosis and Screening

By LabMedica International staff writers
Posted on 07 Jun 2015
Researchers have developed a system that could quickly and reliably identify people infected with Mycobacterium tuberculosis and simultaneously differentiate from those who have received the bacillus Calmette-Guerin (BCG) vaccine for tuberculosis (TB).

Early identification is required to reduce the growing worldwide healthcare burden of TB. More...
One of the biggest hurdles is to differentiate people infected with TB from those who have received the BCG vaccine. An international research team from Malaysia and Iran, led by Taha Roodbar Shojaei and Mohamad Amran Mohd Salleh of Universiti Putra Malaysia (Selangor, Malaysia), have developed a layered biosensor using modified quantum dots, gold nanoparticles, and single-strand DNAs (two specific oligonucleotides against early secretory antigenic target 6). The sensor not only detects TB in patient sputum but also differentiates positive results from samples of vaccinated people. The sensor requires small amounts of sputum and could therefore be used where limited sample volumes are available.

Using the new sensor, the team has conducted preliminary tests on 50 clinical samples from patients in Tehran who were suspected of having TB. While current PCR-based diagnostic TB tests have an approximately 80% success rate for both sensitivity and specificity, the sensor test (based on this initial sample set) had 94.2% sensitivity and 86.6 % specificity. Its unique advantages in terms of turnaround time, higher sensitivity and specificity, as well as a lower (10-fold) detection limit would recommend this test as a more appropriate and cost-effective tool for large scale operations.

In 2015, the team is working to further enhance the biosensor with carbon nanoparticles instead of gold. They also plan to develop the device and interface to further simplify detection, perhaps with a smartphone app.

The report, by Shojaei TR, et al, was published in the November-December 2014 issue of the Brazilian Journal of Infectious Diseases.

Related Links:

Universiti Putra Malaysia



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Blood Glucose Reference Analyzer
Nova Primary
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.